In vitro antiviral activity of favipiravir and its 6‐ and 3‐O‐substituted derivatives against coronavirus: Acetylation leads to improvement of antiviral activity

Abstract

AbstractFavipiravir is currently approved for the treatment of the influenza virus and has shown encouraging results in terms of antiviral capacity in clinical studies against severe acute respiratory syndrome coronavirus 2. Favipiravir is a prodrug, where its favipiravir‐ribofuranosyl‐5B‐triphosphate metabolite is capable of blocking RNA replication of the virus. However, the antiviral efficiency of favipiravir is limited by two factors: (i) low accumulation in plasma and rapid excretion/elimination post‐administration and (ii) low conversion rate into the active metabolite. To tackle these problems, herein, we have designed new favipiravir analogues focusing on the replacement of the fluorine atom at the 6‐position by halogen or hydrogen atoms and 3‐O‐functionalization with labile groups. The first type of functionalization seeks to increase the antiviral activity because of the better ability of the keto‐tautomer as a function of the halogen, and it is hypothesized that the keto‐tautomer tends to promote the formation of the ribofuranosyl‐5B‐triphosphate (RTP) metabolite. Meanwhile, the second type of functionalization seeks to promote lipophilicity and increase accumulation in cells. From the in vitro antiviral activity against two coronavirus models (bovine and human 229E), it was identified that the replacement did not improve the antiviral activity against both the models, which seems to be attributable to the low water solubility of these new 6‐functionalized analogues. Meanwhile, with 3‐O‐functionalization, acetylation provided the most active compounds with higher half‐maximal inhibitory concentration and selectivity than favipiravir, whereas benzylation/methanosulfonation yielded the least active compounds. In summary, acetylation is found to be a convenient functionalization to enhance the antiviral profile of favipiravir.